Grains of paradise extract,
does it really help with Brown-fat activation, increased energy expenditure, and body-fat reduction?
research showsHuman efficacy trials of grains of paradise extract exist, so the grade is not '?'. Increased resting energy expenditure was reported in an acute crossover trial of 19 men and a 4-week crossover trial of 19 women, and a manufacturer-linked trial with 70 randomized participants reported lower weight and visceral fat after 12 weeks. However, samples were small, early trials centered on metabolic markers, and the longer positive trial was conducted by manufacturer employees, so the overall grade is C.
ads claimAdvertising uses phrases such as 'brown-fat switch,' 'accelerated thermogenesis,' 'higher metabolic rate,' and 'abdominal-fat burning.' Research measured short-term resting energy expenditure, response by BAT status, and 12-week body-composition changes with a specific product; it did not establish sustained weight loss or clinical benefit.
Useful facts when choosing a product
- Early studies used 30-40 mg/day of extract, whereas the 2022 AfperFit® trial used 500 mg/day, so the preparations are not identical.
- The energy-expenditure response in the acute male trial occurred only in BAT-positive participants.
- The positive 12-week trial was conducted by employees of the AfperFit® ingredient company.
- Major adverse events were not prominent in short trials, but long-term, drug-combination, pregnancy, and lactation safety data are insufficient.
What the research actually shows
Sugita 2013 used a single-dose crossover trial in 19 healthy young men and reported that 40 mg of extract increased energy expenditure in 12 BAT-positive participants but not in seven BAT-negative participants. Sugita 2014 gave 19 nonobese women 30 mg/day for four weeks and reported higher resting energy expenditure and a difference in visceral-fat area, while changes in total and subcutaneous fat were nonsignificant. Sudeep 2022 randomized 70 participants for 12 weeks and reported reductions in weight, BMI, waist circumference, and visceral fat with 500 mg/day AfperFit®, but the researchers were employed by the ingredient company.
Why this is classified as C (43)
Brown-fat activation and energy expenditure are each C because they rely on a few short surrogate-marker trials. Body fat and weight are C because one 12-week manufacturer-linked positive trial lacks independent replication. The three subclaims combine to C with 46 points, and safety is unknown because long-term data are limited.
Counterpoint. An acute thermogenic response in some people with detectable brown fat and a short-term body-composition effect from a specific standardized preparation remain possible.
Rejudgment record. New judgment — BAT and energy expenditure are small short-term surrogate studies, while positive weight and visceral-fat evidence is concentrated in a proprietary manufacturer study, so boundary rules ① and ②-b cap the grade at C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Brown-fat activation | C | An acute metabolic marker stratified by BAT status in a 19-person single-dose trial |
| Increased energy expenditure | C | A surrogate outcome from two small short-term trials and a manufacturer-linked trial |
| Body-fat reduction | C | A 12-week proprietary manufacturer trial was positive, but total-body-fat results and independent replication are limited |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Sugita et al. 2013 | Single-dose, single-blind, randomized, placebo-controlled crossover trial | 7 | Japanese public research funding; Kanebo Cosmetics researchers participated | Indirect-calorimetry energy expenditure and BAT status | Energy expenditure increased after 40 mg only in the BAT-positive group. | Acute surrogate |
| Sugita et al. 2014 | 4-week single-blind, randomized, placebo-controlled crossover trial | 19 | Kanebo Cosmetics researchers participated; external funding details unclear | Resting energy expenditure and visceral, subcutaneous, and total fat areas | Differences in energy expenditure and visceral-fat area with 30 mg/day; total and subcutaneous fat were nonsignificant. | Short-term surrogate |
| Sudeep et al. 2022 | 12-week randomized, double-blind, placebo-controlled RCT | 60 | Authors employed by Vidya Herbs; proprietary AfperFit® product | Energy expenditure, weight, BMI, waist circumference, visceral fat, and total body fat | Energy expenditure, weight, BMI, waist, and visceral fat improved with 500 mg/day; the between-group total-body-fat difference was nonsignificant. | Positive and manufacturer-linked |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Grains of paradise extract (Aframomum melegueta) x brown-fat activation, increased energy expenditure, and body-fat reduction — Evidence Grade C·43. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/weight/grains-of-paradise-brown-fat-energy-body-fat/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.